Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: Focus on future developments

Clinical and Translational Imaging

Volumn 2, Issue 1, 2014, Pages 55-66

  Bison, Sander M ^a   Konijnenberg, Mark W ^a   Melis, Marleen ^a   Pool, Stefan E ^a   Bernsen, Monique R ^a   Teunissen, Jaap J M ^a   Kwekkeboom, Dik J ^a   de Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Dosimetry; Neuroendocrine tumor; Peptide receptor radionuclide therapy; Somatostatin analogs

Indexed keywords

CAMPTOTHECIN; CISPLATIN; DOTATOC; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; MITOMYCIN; OCTREOTIDE; RADIOSENSITIZING AGENT; SOMATOSTATIN DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; DRUG TUMOR LEVEL; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; INTERNALIZATION; MULTIMODALITY CANCER THERAPY; NEUROENDOCRINE TUMOR; NEUTRON DOSIMETRY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCINTISCANNING;

EID: 84919922910     PISSN: 22815872     EISSN: 22817565     Source Type: Journal    
DOI: 10.1007/s40336-014-0054-2     Document Type: Review

References (94)

1. Hemminki K, Li X (2001) Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 92(8): 2204-2210.
2. Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13, 715 carcinoid tumors. Cancer 97(4): 934-959.
3. Yao JC et al (2008) One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol 26(18): 3063-3072.
4. Modlin IM et al (2006) Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 4(5): 526-547.
5. Kwekkeboom DJ et al (2010) Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 40(2): 78-88.
6. 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging 38(12): 2125-2135.
7. 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging 34(8): 1219-1227.
8. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 12(7): 941-945.
9. Taniyama Y et al (2005) Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J 52(5): 605-611.
10. Reubi JC et al (1990) Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 50(18): 5969-5977.
11. Reubi JC et al (2001) Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28(7): 836-846.
12. Patel YC (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20(3): 157-198.
13. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20(8): 716-731.
14. 111In -DTPAo]octreotide in patients. Eur J Nucl Med 28(9): 1319-1325.
15. Rosenberg JM (1988) Octreotide: a synthetic analog of somatostatin. Drug Intell Clin Pharm 22(10): 748-754.
16. Rinke A et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27(28): 4656-4663.
17. 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging 39(Suppl 1): S52-S60.
18. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging 33(10): 1123-1133.
19. 99mTc-TOC) for imaging neuroendocrine tumors. Nucl Med Commun 33(1): 69-79.
20. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 37(7): 1441-1448.
21. 3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48(4): 508-518.
22. 68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28(12): 1751-1757.
23. Rosch F, Baum RP (2011) Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS. Dalton Trans 40(23): 6104-6111.
24. Valkema R et al (2002) Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 32(2): 110-122.
25. Anthony LB et al (2002) Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 32(2): 123-132.
26. 90)Y-DOTATOC. J Nucl Med 43(5): 610-616.
27. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 30(2): 207-216.
28. Valkema R et al (2006) Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36(2): 147-156.
29. Kwekkeboom DJ et al (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26(13): 2124-2130.
30. Fani M, Maecke HR, Okarvi SM (2012) Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics 2(5): 481-501.
31. Teunissen JJ et al (2011) Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relate Cancer 18(Suppl 1): S27-S51.
32. Ginj M et al (2006) Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 103(44): 16436-16441.
33. 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med 52(12): 1886-1890.
34. Wild D et al (2011) First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med 52(9): 1412-1417.
35. Putzer D et al (2013) Somatostatin receptor PET in neuroendocrine tumours: 68 Ga-DOTA0, Tyr3-octreotide versus 68 Ga-DOTA0-lanreotide. Eur J Nucl Med Mol Imaging 40(3): 364-372.
36. 3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol 12(Suppl 2): S41-S45.
37. Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24(4): 389-427.
38. Wang X et al (2012) Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. Eur J Nucl Med Mol Imaging 39(12): 1876-1885.
39. Tulipano G et al (2002) Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology 143(4): 1218-1224.
40. 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med 52(7): 1110-1118.
41. O'Donoghue JA, Bardies M, Wheldon TE (1995) Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36(10): 1902-1909.
42. 90Y-labeled somatostatin analogs. J Nucl Med 46(Suppl 1): 13S-17S.
43. 177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging 38(10): 1788-1797.
44. 177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 30(10): 1100-1106.
45. Savolainen S et al (2012) Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail. Eur J Nucl Med Mol Imaging 39(3): 548-549.
46. 177Lu in human pancreatic adenocarcinoma cells. Nucl Med Biol 34(2): 185-193.
47. Miederer M et al (2008) Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res 14(11): 3555-3561.
48. Dodson H, Wheatley SP, Morrison CG (2007) Involvement of centrosome amplification in radiation-induced mitotic catastrophe. Cell Cycle 6(3): 364-370.
49. 213Bi-DOTATOC radiopeptide therapy using contrast-enhanced ultrasound in liver metastatic neuroendocrine cancer. Eur J Nucl Med Mol Imaging 38(Suppl. 2): S117.
50. Kulke MH et al (2009) O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15(1): 338-345.
51. Limouris GS et al (2008) Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging 35(10): 1827-1837.
52. Kratochwil C et al (2011) Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr Relat Cancer 18(5): 595-602.
53. 111In-DTPA-octreotide by loco regional administration. Eur J Nucl Med Mol Imaging 36: S427.
54. 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res 16(10): 2899-2905.
55. 90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 29(17): 2416-2423.
56. 177Lu-Octreotate. J Nucl Med 54: 1857-1861.
57. Rolleman EJ et al (2003) Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 30(1): 9-15.
58. 90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 46(Suppl 1): 99S-106S.
59. Wessels BW et al (2008) MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response-implications for radionuclide therapy. J Nucl Med 49(11): 1884-1899.
60. Valkema R et al (2005) Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 46(Suppl 1): 83S-91S.
61. 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 35(10): 1847-1856.
62. 90Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors. Biomed Res Int 2013: 935351.
63. 3-octreotide (SMT487)-a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 30(4): 510-518.
64. Garkavij M et al (2010) 177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer 116(4 Suppl): 1084-1092.
65. 177Lu-DOTA-octreotate treatment. J Nucl Med. 54(1): 33-41.
66. 111)In-DTPA]octreotide. J Nucl Med 45(7): 1168-1171.
67. Konijnenberg M et al (2007) Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med 48(1): 134-142.
68. Baechler S et al (2012) Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy. Med Phys 39(10): 6118-6128.
69. Forrer F et al (2009) Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 36(7): 1138-1146.
70. Hindorf C et al (2010) EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging 37(6): 1238-1250.
71. Lassmann M et al (2008) EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 35(7): 1405-1412.
72. 90Y-DOTATOC therapy and relationship to the decrease of platelet counts. Eur J Nucl Med Mol Imaging. 38(7): 1270-1280.
73. Arvold ND et al (2012) Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 83(3): e337-e343.
74. 90)Y-labeled somatostatin analogs. J Nucl Med 46(Suppl 1): 92S-98S.
75. 177Lu-octreotate. Nuklearmedizin 52(5): 170-177.
76. Otte A et al (1999) Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 26(11): 1439-1447.
77. 177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. Cancer Imaging. 11: 56-66.
78. Sabet A et al (2014) Outcome and toxicity of salvage therapy with Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 41: 205-210.
79. 177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 51(3): 383-390.
80. Breeman WA et al (2003) Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0, Tyr3]octreotate in a rat liver micrometastases model. Int J Cancer 104(3): 376-379.
81. Kaemmerer D et al (2009) Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 15(46): 5867-5870.
82. 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg 395(2): 185-192.
83. 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Cancer Biother Radiopharm 27(9): 561-569.
84. Barber TW et al (2012) The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. Eur J Surg Oncol 38(1): 64-71.
85. 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 35(4): 743-748.
86. 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 38(2): 302-311.
87. Fueger BJ et al (2001) Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. J Nucl Med 42(12): 1856-1862.
88. Jain RK (2013) Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 31(17): 2205-2218.
89. Bison SM, Haeck JC, Koelewijn SJ, Groen HC, Berndsen S, Melis M, Bernsen MR, de Jong M (2013) Optimization of combination of peptide receptor radionuclide therapy (PRRT) and temozolomide therapy using SPECT/CT and MRI in mice. Eur J Nucl Med Mol Imaging 40(suppl 2): S290(abstract).
90. Nayak TK et al (2008) Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation. Nucl Med Biol 35(6): 673-678.
91. Yao JC et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6): 514-523.
92. Fingar DC, Blenis J (2004) Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23(18): 3151-3171.
93. Pool SE et al (2013) mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreaticneuroendocrine cancer. Cancer Res 73: 12-18.
94. 111In-octreotide. Eur J Nucl Med Mol Imaging 37(10): 1869-1875.